FLGT - Fulgent Genetics, Inc.
NASDAQ
->
Healthcare
->
Diagnostics & Research
Temple City,
United States
Type: Equity
FLGT price evolution
FLGT
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $65.11 | $54.68 | $97.47 | |
| Short term investments | $246.59 | $251.02 | $326.68 | |
| Net receivables | $64.89 | $56.57 | $52.06 | $51.13 |
| Inventory | ||||
| Total current assets | $326.54 | $399.1 | $386.51 | $507.85 |
| Long term investments | $546.6 | $560.93 | $444.01 | |
| Property, plant & equipment | $113.69 | $93.37 | $86.72 | $83.46 |
| Goodwill & intangible assets | $161.03 | $163.04 | $165.11 | |
| Total noncurrent assets | $833.13 | $843.38 | $727.48 | |
| Total investments | $793.2 | $811.95 | $770.69 | |
| Total assets | $1233.76 | $1232.24 | $1229.88 | $1235.33 |
| Current liabilities | ||||
| Accounts payable | $19.8 | $19.87 | $19.62 | $15.36 |
| Deferred revenue | $2.74 | $2.76 | $2.87 | |
| Short long term debt | $0.41 | $0.41 | $1.18 | |
| Total current liabilities | $73.99 | $75.75 | $75.95 | $73.02 |
| Long term debt | $0.45 | $0.54 | $0.62 | $3.76 |
| Total noncurrent liabilities | $27.64 | $27.29 | $29.02 | |
| Total debt | $0.41 | $0.41 | $1.18 | |
| Total liabilities | $95.32 | $103.39 | $103.24 | $102.04 |
| Shareholders' equity | ||||
| Retained earnings | $596.36 | $611 | $619.71 | $633.17 |
| Other shareholder equity | $9.18 | -$0.88 | -$1.1 | $1.21 |
| Total shareholder equity | $1132.55 | $1129.94 | $1136.1 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $97.47 | $79.51 | $164.89 | $87.43 |
| Short term investments | $326.68 | $446.73 | $285.61 | $211.94 |
| Net receivables | $51.13 | $90.54 | $138.91 | $183.86 |
| Inventory | ||||
| Total current assets | $507.85 | $627.87 | $611.96 | $523.62 |
| Long term investments | $444.01 | $339.03 | $507.01 | $132.5 |
| Property, plant & equipment | $83.46 | $98.92 | $62.29 | $41.03 |
| Goodwill & intangible assets | $165.11 | $293.67 | $86.81 | |
| Total noncurrent assets | $727.48 | $758.18 | $666.76 | $176.84 |
| Total investments | $770.69 | $785.76 | $792.62 | $344.44 |
| Total assets | $1235.33 | $1386.05 | $1278.72 | $700.46 |
| Current liabilities | ||||
| Accounts payable | $15.36 | $23.09 | $20.49 | $26.49 |
| Deferred revenue | $2.87 | $3.2 | $14.57 | $26.58 |
| Short long term debt | $1.18 | $20.64 | $21.28 | $15.29 |
| Total current liabilities | $73.02 | $88.11 | $105.31 | $130.12 |
| Long term debt | $3.76 | $1.82 | $1.4 | $0.57 |
| Total noncurrent liabilities | $29.02 | $28.07 | $7.53 | $0.96 |
| Total debt | $1.18 | $20.64 | $21.28 | $15.85 |
| Total liabilities | $102.04 | $119.37 | $112.84 | $131.07 |
| Shareholders' equity | ||||
| Retained earnings | $633.17 | $801 | $657.6 | $150.88 |
| Other shareholder equity | $1.21 | -$20.9 | -$0.76 | $0.44 |
| Total shareholder equity | $1136.1 | $1266.68 | $1158.75 | $569.39 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $71.74 | $71.03 | $64.48 | $70.5 |
| Cost of revenue | $44.54 | $42.38 | $45.28 | |
| Gross Profit | $26.77 | $26.49 | $22.1 | $25.23 |
| Operating activities | ||||
| Research & development | $13.49 | $11.43 | $11.95 | |
| Selling, general & administrative | $29.92 | $30.48 | $42.21 | |
| Total operating expenses | $43.85 | $45.4 | $43.9 | $176.35 |
| Operating income | -$18.91 | -$21.8 | -$151.12 | |
| Income from continuing operations | ||||
| EBIT | -$10.83 | -$13.79 | -$139.01 | |
| Income tax expense | -$3.84 | -$2.12 | -$0.33 | -$10.86 |
| Interest expense | $8.08 | |||
| Net income | ||||
| Net income | -$14.65 | -$8.71 | -$13.46 | -$128.15 |
| Income (for common shares) | -$8.71 | -$13.46 | -$128.15 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $289.21 | $618.97 | $992.58 | $421.71 |
| Cost of revenue | $184.76 | $252.07 | $215.53 | $89.81 |
| Gross Profit | $104.46 | $366.9 | $777.05 | $331.9 |
| Operating activities | ||||
| Research & development | $41.44 | $28.91 | $24.22 | $11.58 |
| Selling, general & administrative | $130.47 | $149.99 | $75.17 | $30.17 |
| Total operating expenses | $299.99 | $188.37 | $101.1 | $41.75 |
| Operating income | -$195.53 | $178.53 | $675.95 | $290.16 |
| Income from continuing operations | ||||
| EBIT | -$166.67 | $185.5 | $682.16 | $286.84 |
| Income tax expense | $1.15 | $42.1 | $174.79 | $72.53 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$167.82 | $143.4 | $507.36 | $214.31 |
| Income (for common shares) | -$167.82 | $143.4 | $507.36 | $214.31 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$8.71 | -$13.46 | -$128.15 | |
| Operating activities | ||||
| Depreciation | $7.32 | $8.17 | $8.05 | |
| Business acquisitions & disposals | -$0.4 | |||
| Stock-based compensation | $11.63 | $11.52 | $11.43 | |
| Total cash flows from operations | $4.29 | $7.27 | $14.93 | |
| Investing activities | ||||
| Capital expenditures | -$12.93 | -$3.8 | -$2.77 | |
| Investments | $20.23 | -$43.39 | $27.44 | |
| Total cash flows from investing | -$30.9 | $7.3 | -$47.19 | $24.27 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$0.23 | -$22.86 | ||
| Net borrowings | -$0.6 | -$0.9 | -$1.98 | |
| Total cash flows from financing | -$4.52 | -$1.15 | -$2.81 | -$25.95 |
| Effect of exchange rate | $0.08 | -$0.01 | -$0.07 | $0.14 |
| Change in cash and equivalents | -$39.3 | $10.43 | -$42.8 | $13.4 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$167.82 | $143.4 | $507.36 | $214.31 |
| Operating activities | ||||
| Depreciation | $32.55 | $37.58 | $12.16 | $3.37 |
| Business acquisitions & disposals | -$0.4 | -$182.68 | -$61.87 | |
| Stock-based compensation | $42.92 | $32.64 | $15.88 | $8.16 |
| Total cash flows from operations | $27 | $253.52 | $538.58 | $140.63 |
| Investing activities | ||||
| Capital expenditures | -$21.43 | -$18.36 | -$23.75 | -$36.5 |
| Investments | $60.73 | -$60.27 | -$460.9 | -$289.94 |
| Total cash flows from investing | $38.9 | -$261.31 | -$546.55 | -$326.44 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$25.06 | -$74.31 | $89.56 | $246.23 |
| Net borrowings | -$20 | -$1.07 | -$0.01 | $15.02 |
| Total cash flows from financing | -$47.78 | -$77.14 | $85.41 | $261.25 |
| Effect of exchange rate | -$0.15 | -$0.45 | $0.03 | $0.02 |
| Change in cash and equivalents | $17.97 | -$85.39 | $77.47 | $75.46 |
News
Fundamentals
| Market cap | $508.14M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 30.54M |
| Revenue | $277.76M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$164.97M |
| Revenue Q/Q | -15.28% |
| Revenue Y/Y | -3.02% |
| P/E ratio | -3.08 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 1.83 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$5.40 |
|---|---|
| ROA | -13.38% |
| ROE | N/A |
| Debt/Equity | 0.09 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 4.41 |
| Quick ratio | N/A |